The Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients

Cerebral microbleeds（CMBs） is a subclinical lesion caused by microvascular disease in the brain, characterized by microleakage of blood. About 30% of ischemic stroke patients, 40% of the healthy people over 80 years old, and 60% of intracranial hemorrhage patients have microbleeds. With the development of imaging technology, clinically more and more patients have found microbleeds in the brain. How these patients are treated with antithrombotic drugs is not yet clear and is in urgent need of evidence. There are only a few prospective cohort studies to determine whether antithrombotic therapy increases the risk of intracranial hemorrhage in ischemic stroke patients with CMBs, but the results are uncertain. More importantly, whether antithrombotic therapy increases the incidence of the emerging CMBs, and whether the change of increased microbleeds is associated with increased intracranial hemorrhage has not been reported.

Inclusion criteria

• Patient age ≥18 years;
• Acute ischemic stroke patient confirmed by imaging;
• Time of onset: within 3 months;
• Baseline SWI sequence is completed before starting the secondary prevention of ischemic stroke;
• Baseline SWI sequence must have at least one CMB ;
• NIHSS≤10

Exclusion criteria

• MRI contraindication;
• Hemorrhagic transformation after acute Ischemic stroke;
• Contraindication for antiplatelet or anticoagulation therapy;
• Severe head trauma or intracranial hemorrhage occurred in the past six months;
• obvious coagulopathy;
• Other intracranial lesions associated with (such as tumor, cerebral vascular malformation);
• other unqualified patients judged by the investigator